Sarcoidosis drug dilemma: stop or stay?
NCT ID NCT05689879
First seen Feb 04, 2026 · Last updated May 04, 2026 · Updated 17 times
Summary
This study looks at whether people with sarcoidosis who are in remission should stop taking the drug infliximab or continue it to prevent the disease from coming back. The trial involves 32 adults who have been on infliximab for at least 6 months and are currently stable. Researchers will compare how many people in each group have a major relapse within a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital de la Pitié-Salpêtrière
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.